A cartilage-derived inhibitor of angiogenesis may control deregulated vascular growth characteristic of angiogenic diseases by inhibiting metalloproteinase activity.
Metalloproteinases and their endogenous inhibitors are key components of an enzyme system which is important in a number of fundamental biochemical and cellular processes. Our recent work has focused on the role of a particular metalloproteinase, collagenase, and the role of an endogenous inhibitor of this enzyme in the control of neovascularization. The proteolytic degradation of extracellular matrix components by capillary endothelial cells (EC) has been shown to be one of the key prerequisites of the angiogenic process. As part of a study of the effect(s) of the inhibition of collagenase on neovascularization, we have recently reported the purification, characterization and partial NH2-terminal sequence of a cartilage-derived inhibitor (CDI) of angiogenesis in vivo and in vitro. Evidence is presented which suggests that one means of controlling deregulated vascular growth characteristic of a number of "angiogenic diseases" may be at the level of the control of metalloproteinase activity.
Moses et al. (Fri,) conducted a review in Angiogenic diseases. Cartilage-derived inhibitor (CDI) of angiogenesis was evaluated on Neovascularization / angiogenesis. A cartilage-derived inhibitor of angiogenesis may control deregulated vascular growth characteristic of angiogenic diseases by inhibiting metalloproteinase activity.